SHANGHAI, June 1, 2018 /PRNewswire/ — On May 26, 2018, the Second OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was held in Shanghai. On the theme of “Broader Vision, Deeper Insight”, Chinese and foreign experts and scholars in this summit carried out further discussion on such topics as tumor targeting and immunotherapy, aiming to benchmark China’s precision treatment against international standards. 

For this summit, four experts in precision medicine from the Scientific Advisory Board of OrigiMed, including Professor Matthew Meyerson, a leader in cancer genomics and targeted therapy from Harvard Medical School and a founder of the cancer NGS company Foundation Medicine, Professor Gordon Freeman, a pioneer in immunotherapy from Harvard Medical School, Professor Carlos L. Arteaga, expert in translational research in breast cancer and director of the Simmons Cancer Center at UT Southwestern in Dallas and Professor Tony Mok, international lung cancer expert from the Faculty of Medicine of the Chinese University of Hong Kong, gathered in Shanghai to show their cutting-edge research results in precision treatment for attendees. In addition, honored guests such as Professor Wu Yilong, lifetime director of Guangdong General Hospital, Professor Chen Haiquan, director of the Thoracic Surgery Department at Fudan University Cancer Center in Shanghai, and Professor John Cai, director of CEIBS Center for Health Care Management and Policy, were invited to cast new light upon issues of public concern like the transformation of precision medicine to clinical practice, and the development policies and economic relationships of targeted medicine and immunotherapy, providing new thinking and a breakthrough point for cancer treatment in China.

Generally speaking, precision medicine is a medical model that proposes the customization of healthcare. In this model, diagnosis and therapy are made based on a patient’s tumor genetic content or other molecular or cellular analysis, with medical decisions, treatments, practices, or products being tailored to the need of the patient. Basically, cancer is a genetic disease. Every cancer is caused by the mutation of specific genes, allowing precision testing before precision treatment. Only when the type of cancer gene mutation is clearly defined can the correct selection of targeted therapies be made to truly benefit patients. In America, the coverage of over 300 tumor gene detection products in health insurance by FDA means great changes in cancer treatment. In the future, gene detection will not only provide cancer patients with more personalized medical services, but also reduce their financial pressure.

At the first experts’ meeting on precision medicine strategy hosted by the Ministry of Science and Technology in 2015, it was announced that investment totaling CNY 60 billion is expected in this sector by 2030. Precision medicine has become a nationwide initiative since then. Although still in its infancy in China, precision medicine is bound to benefit the large population of cancer patients with the substantial support of government. In such context, the OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy is of particular value.

In this summit, based on accurate detection techniques and international leading biodata analysis, OrigiMed released multiple new findings for cancer patients in China that had never been reported before. These findings will be practically and effectively applied in cancer treatment. OrigiMed also provided multiple international clinical research platforms. Since establishment, OrigiMed has built many international platforms such as a world leading international scientific advisory team, an international platform for clinical exchange and discussion, and international cooperation platforms for precision treatment of hepatobiliary tumor and breast cancer. OrigiMed has greatly promoted the precision, individualization and internationalization of cancer treatment in China.

“Precision treatment is a cutting-edge front in tumor studies and precision detection is a prerequisite for precision treatment. Our goal is to identify the origin of cancer and provide a more individualized precise treatment for each patient.” Dr. Wang Kai, CEO of OrigiMed said. “In the past, we’re only able to test one gene in a single detection. But now, several hundred genes can be tested at the same time with higher precision using next generation sequencing techniques (NGS). Based on the optimization algorithm and strong knowledge base developed by our company, patients can get accurate and broad information about various mutations of several hundred cancer genes through samples of the same size. Only in this way can the needs of clinically precise individualized treatment be met. In the future, we also hope to build more international collaboration platforms and work with domestic and foreign industry experts and peers to promote the development of precision medicine in China and fight against cancer together. We at OrigiMed believe this will ensure that once precision medicine becomes standard of care, cancer patients in China will benefit from this progress with prolonged good quality of life and lower mortality.”

Professor Matthew Meyerson, expert in cancer genomics and director of cancer genomics at both the Broad Institute of MIT and Harvard University and the Dana-Farber Cancer Institute, expressed that he was honored to join the Scientific Advisory Board of OrigiMed. He hopes that OrigiMed will make further progress in NGS and precise treatment to provide clinical assistance to cancer patients, with the comprehensive detection of hundreds of genes applied in clinical practice.

Professor Wu Yilong, one of the members in the presidium and lifetime director of Guangdong General Hospital, said that China’s precise treatment would play an increasingly important role in the international community since China has entered into an era of rapid change and reform in medicine. With the upcoming commercialization of China’s first checkpoint inhibitor in 2018, clinical trials should be conducted for immunotherapy and precision detection employed to select optimal biomarkers to provide effective treatment for more patients. Dr. Wu pointed out that powerful biodata analysis techniques and capabilities would play an important role in future precision treatment.

The summit was sponsored by OrigiMed, which was founded in May 2016. With capital from IDG Ventures, Green Pine Capital Partners, Wedo Capital, Star VC and other famous investment institutions at home and abroad, OrigiMed upholds the core principle of “Tracing Cancer Back to the Origins” and is committed to the R&D of new diagnosis and treatment technologies to be applied in clinical practice for all cancer patients across China. By carrying out comprehensive detection of 450 cancer genes via NGS and its innovative technologies tailored to clinical needs, OrigiMed offers one-stop precision detection, featuring six major clinical functions. In addition, OrigiMed launched the first mobile application of precision treatment data in China, Doctor Marmot, which has provided more assistance for clinical treatment. At present, the clinical detection service network of OrigiMed covers more than 200 core hospitals in over 40 key cities nationwide.

View original content with multimedia:http://www.prnewswire.com/news-releases/second-origimed-summit-for-cancer-discovery-held-in-shanghai-bringing-precision-medicine-of-china-to-go-global-300657847.html

BOTHELL, Washington, May 30, 2018 /PRNewswire/ — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming BIO International Convention in Boston, Mass. on June 4-7, 2018.

Newly rebranded in January 2018, AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. This will be the first BIO International Convention attended by AGC Biologics as a single, global CDMO with more than 55 years of combined industry experience. With an expanding network of cGMP facilities across the globe, and demonstrated proficiency with innovative technologies and solutions, the growing company has actively exhibited a proven commitment to meet the demands of the dynamic, fast-growing market.

AGC Biologics’ President and Chief Executive Officer, Gustavo Mahler, Ph.D., will deliver a talk at the BioProcess International Theater on Wednesday, June 6 at 2:00 pm. The presentation will be included in the track: Emerging Techniques, Technologies, and Strategies: Outsourcing/ Continuous Processing/Single-Use/Assays, and will focus on Emerging Technologies & Strategies to Accelerate Process Development and Time to Market.

AGC Biologics will exhibit and host meetings at Booth #663 in the BioProcess Zone.

“This year’s BIO International Convention is a meaningful venue to exhibit and participate under our new name, AGC Biologics,” said Bob Broeze, Chief Business Officer at AGC Biologics. “We look forward to meeting with our wide range of clients and industry colleagues, as well as fostering new connections and relationships, and further establishing AGC Biologics as an industry-leading CDMO with a significant and growing presence in the global marketplace.”

About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.

AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1^® Expression System for mammalian production. Further information can be found at www.agcbio.com

AGC Biologics Media Contact Information:
Ms. Kim Yang
Director, Global Marketing and Communications
Email: kyang@agcbio.com 
Office: +1 425.415.5438

Logo – https://mma.prnewswire.com/media/624983/AGC_Biologics_logo_Logo.jpg   

NUSSLOCH, Germany, May 31, 2018 /PRNewswire/ — Leica Biosystems announces the addition of a new family of Rotary Microtomes to its full line of histology equipment and consumables. The line-up includes the HistoCore BIOCUT, HistoCore MULTICUT and HistoCore AUTOCUT clinical microtomes. Each instrument provides high quality sections and ease of use, while delivering enhanced safety for the user.

Leica Biosystems HistoCore Microtome Clinical Series

“We are very excited to introduce the next generation of clinical microtomes based on our 145 years of experience in microtomy,” stated Peter Reimer, Vice President Core Histology, Leica Biosystems. “Through listening to our customers, we have developed a family of microtomes that will help provide consistent quality and enhanced efficiency, while maintaining a safe and healthy workplace for the user,” said Reimer.

Head of Laboratory, Mengia Berthold and Deputy Head of Laboratory, Karin Portmann, Pathology Laenggasse stated, “After using the HistoCore MULTICUT and AUTOCUT, we noticed the stability of the instruments and high quality sectioning. The new coarse feed wheels allows us to trim our blocks faster, and the antistatic waste tray makes cleaning quick and easy. Our lab techs immediately noticed the new product design and the larger surface top for storing tools and consumables.”

The HistoCore Rotary Microtomes deliver improved comfort through ergonomic positioning and adapting the coarse feed wheel to the user’s preference, helping reduce fatigue while trimming.  In addition, the unique force balance system reduces the risk of injury from an unbalanced object head.

For increased flexibility, users can produce high quality paraffin sections for H&E, IHC and molecular techniques. Additionally, a 2-in-1 blade holder provides the flexibility to use both high and low profile blades.

An optional antistatic waste tray increases efficiency by shortening cleaning time from minutes to seconds and reduces contamination to the user/environment by effectively collecting and containing waste. Also, a specimen cooling option allows for the block temperature to stay colder longer using the electrically cooled RM CoolClamp for standard cassettes.

The HistoCore Rotary Microtomes offer rapid specimen exchange with fast homing and programmable memo position (MULTICUT and AUTOCUT) and an electronic brake for safe blade and specimen handling (AUTOCUT).

About Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis.  Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

18675

Media Contact: Courtney Hill, Global Brand Marketing Specialist
Phone: +1.847.405.7041
LBS-GlobalMarketing@leicabiosystems.com

Photo – https://mma.prnewswire.com/media/698683/Histore_Microtome_Clinical_Series.jpg

SHANGHAI, May 30, 2018 /PRNewswire/ — As the medical device industry in China is developing in the direction of high-technology, the Chinese government is encouraging the internationalization of local innovative medical device production to explore global marketing opportunities. Medtec China, as one of the leading show dedicated in medical device design and manufacturing in China, will be held 26-28 September in Shanghai to continue contributing to accelerate the pace of development. This year’s show will launch a new exhibiting zone called REGULATORY STREET, which is exclusively supported by Shanghai Pudong Medical Device Trade Association, consultant companies and keynote speakers from North America, Europe and China, with regulatory updates for China, the US and the EU provided in this zone. Meanwhile, the China Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMHPIE) is also joining hands with Medtec China 2018 to hold a seminar to discuss how to accelerate the internationalization of the medical device industry in China and what are the challenges and opportunities in this process.

Medtec China Logo

REGULATORY STREET helps local brand go global

With the rapid development of Chinese medical device manufacturing, more and more competitive products are being exported to the US, EU and other regions around the world. Therefore, local regulation compliance and certification is very important for them. This regulatory zone was also launched for this reason. Shanghai Pudong Medical Device Trade Association acknowledges this intention and fully supports the activity.

Exhibitors in REGULATORY STREET provide comprehensive regulatory consultant services including accessing markets in North America, Europe, Japan and Canada. For example, Dr. Knoell Consult GmbH offers client-specific strategic advice for the global registration of medical devices. They assist companies in designing quality management systems and the associated support for preparation and up-keeping of technical documentations. As a leader in the medical device industry for many years, WuXi AppTec provide unique testing plans which can be customized at any stage of the product development life cycle. Further, Shanghai Huaxia Investment Management Co, Ltd specializes in enterprise registration, financial agents, trademarks, personnel and other one-stop business services.

2017 Medtec China On Site Conference

Joining hands with CCCMHPIE to hold seminar on high-end medical device production internationalization

The 13^th five-year plan focuses on the development of an advanced domestic medical device industry. To speed up the internationalization of high-end medical device production, CCCMHPIE is going to organize a seminar at Medtec China 2018 to share information about marketing in countries along the Belt and Road and how to solve the challenges of this program. Leaders from the Ministry of Commerce and the deputy of the Deputy Secretary-General of CCCMHPIE will attend the meeting.

Mindray, Neusoft, Shinva, United-Imaging, Sonoscape, WEGO, Yuwell, Fosun and Anke who are members of CCCMHPIE may also join this meeting at Medtec China 2018.

2017 Medtec China On Site

More than 50 companies are going to debut at Medtec China 2018 and in all, 400 suppliers will congregate at this annual event in 26-28 September in Shanghai to showcase exhibits of medical raw materials, components, tubing and extrusion, manufacturing equipment, contract manufacturing services, and regulatory consultant services for more than 10,000 decision makers, purchasing staff, R&D engineers, product engineers and quality inspectors from medical device manufacturers.

Selected debuting exhibiting companies: Wynca is a leading global supplier of silicon-based new material products. Shanghai BAODIE Complete Sets of Plastic Equipment Co., Ltd. is a manufacturer specializing in high speed single/multi-layer medical tube/pipe extrusion lines. Arone is a precision mechanical enterprise in R&D and manufacture including rail transit products, medical devices, and electrical/electronic parts.

Era-contact (Suzhou) Co., Ltd. is from Germany and boasts proficiency at designing and assembling complex electrical systems. It also possesses high-level technology, such as resistance welding, hot melt injection, and glue packaging. EG-MEDACYS is from the USA and they are a one-stop medical devices manufacturer with tooling, molding, assembly and engineering services provided to medical device manufacturers, and biology, lab, consumable and consumer industries. To discover more information about 2018 exhibitors, please click here.

To find more information about Medtec China, please check our official website: www.medtecchina.com.

Media\Exhibit\Visit\Conference Contact:
Carina Li
UBM China
T: +86 10 5730 6163
E: carina.li@ubm.com
Medtec China Organizing Committee

Photo – https://photos.prnasia.com/prnh/20180529/2145045-1-a
Photo – https://photos.prnasia.com/prnh/20180529/2145045-1-b
Photo – https://photos.prnasia.com/prnh/20180529/2145045-1-c

– Held on May 29th with over 700 industry representatives attending

– UV LED technology and product trends, local utilization cases introduced

– “UV LED being utilized to differentiate finished products and resolve sanitation issues”

SEOUL, South Korea, May 30, 2018 /PRNewswire/ — LG Innotek held the “UV LED Forum” at JW Marriott Hotel Bao-an, Shenzhen, Guangdong Province, China on May 29th to share the latest UV LED technology trends. The forum was a great success with over 700 representatives from local industries attending, including those from consumer electronics, sanitation equipment, medical service, and manufacturing equipment.

Ultraviolet (UV) LED is the most advanced semiconductor light source emitting ultraviolet rays. Exterminating germs and viruses depending on the wavelengths, it is widely used for sterilization of water, air and surfaces, also on medical, bio-, hardening of plastics or light exposure devices.

LG Innotek chose Shenzhen as the venue for its first overseas forum based on its belief that China is a market with the biggest potential demand for UV LED. The company wishes to maintain the leading position by directly presenting the outstanding performance and extensive application areas of environment-friendly UV LED to the global market.

“UV LED is an innovative product that can make our life clean and safe. We will actively cooperate in various different sectors so that the industrial ecosystem can grow rapidly,” said CEO Jong-Seok Park in his welcome remarks.

Park Jong Seok, LG Innotek CEO, speech at UV LED Forum

Hong Ray-Hua, professor at Chiao Tung University in Taiwan who is an expert in the engineering fields, explained the values of UV LED for practical use in a keynote speech on that day.

Afterward, the current UV LED application cases in China were introduced by industry leaders, including Ouyang Chenyi, CEO of UV LED Optical, one of the world’s largest nail curing equipment manufacturers, Xiang Yu, merchandise planning supervisor at HCEN, which produces UV modules for water purification, and Wan Tianwei, Managing Director of HaidUV, a manufacturer of UV modules for consumer electric and electronic appliances.

In addition, Professor Dong-hyun Kang of the College of Agriculture and Life Sciences at Seoul National University presented the outcome of his empirical study concerning the sterilizing capacity of UV LED. According to him, UV-C LED with 100mW light output power exterminates 99.9% of salmonellae that causes food poisoning within a mere 3.4 seconds.

Jun-Oh Song, the Vice President of LED business division, introduced the company’s product lineup and development roadmap. “After increasing the light output power of sterilization to UV LED 100mW last year, we plan to enhance it to 150mW in 2018 and 200mW in 2019.”

A UV LED exhibition booth was provided at the event site, attracting keen attention from the visitors by displaying over 30 different UV LED packages including the UV-C LED package that generates 100mW as the world’s highest light output as well as sterilization modules and other applied products developed independently by the company.

“We could see the keen interest of Chinese businesses in UV LED,” said one LG Innotek executive. They hinted at utilizing UV LED in resolving environment and sanitation-related issues while differentiating the functions and quality of their existing products.

Kang Dong Hyun, Seoul National University Professor present UV LED effect

Photo – https://photos.prnasia.com/prnh/20180530/2146284-1-a
Photo – https://photos.prnasia.com/prnh/20180530/2146284-1-b

Join together to break the Guinness World Record

HONG KONG, May 28, 2018 /PRNewswire/ — The first-ever Freefrom Festival in Asia, “Freefrom Festival Hong Kong”, organised by Freefrom Foods International Association (FFIA) will be held during 6–8 July 2018 in Hall 5G, Hong Kong Convention and Exhibition Centre together with Hong Kong Bakery Carnival. (Booth No.: N01 & N03)

Ms. Bonnie Lam, Founder and Chairperson of FFIA, kick-off the “Freefrom Festival Hong Kong” and introduce the activities of the Festival to the media.

Event highlights of the Freefrom Festival Hong Kong include: 1) “The Love Train” — Guinness World Record breaking event, 2) Freefrom Cooking Workshops, and 3) Freefrom Educational zone.

1) “The Love Train” — Invite public to join the Guinness World Record breaking event

Using gluten-free bread to achieve the new world record, “The Longest Line of Bread”, with a total length of 1000 meters will be created during the Festival. The event is titled “The Love Train” as the line of breads symbolise the carts of a train, which spread love, hope and happiness to our society. People who join the event can write their love message on the package of the bread. All gluten-free breads will be donated to charities for those in need after the Festival. Your blessings will be carried by the Love train and drive to the community.

Event Details:
Date & Time: 6-7 July: 10am–8pm; 8 July: 10am–6pm
Registration Fee: HK$220/ pax (*Registration Fee does NOT include Admission ticket)
Registration Fee included: 

1. Participation of “The Love Train” x 1 time
2. A Certificate of participation issued by FFIA
3. “Gluten-free love bag” gift x 1 set

[Registration & Ticketing]
Please visit https://www.freefromfoodsassociation.org/guinness-online-registration for more details.

2) Freefrom Cooking Workshops

Experience a unique cooking class and learn how to make freeform goodies.
Freefrom Recipes: Gluten-free lemon tarts, Dairy-free banana ice-cream, & Gluten-free mini waffle burgers

3) Freefrom Educational zone

A corner to teach the public what food allergy and freeform foods are:

a. Food Allergy — Introduce what food allergy is and how it impacts our daily life.  
What kind of sickness may be caused by food allergy, for example eczema, intestinal health problems, etc.

b. Freefrom foods — Introduce what freefrom food is, how to select freeform foods, etc.

If you have any enquiry, please send email to FFIA: hello@freefromfoodsassociation.org

Freefrom Foods International Association (FFIA)

FFIA was established in Hong Kong in 2018. The prevalence of food allergy and food intolerance in Asia has been increasing. FFIA aims to serve people in need with specialty diets in Hong Kong and Asia, act as a bridge to connect globally, and provide education support and solutions.The mission of FFIA is to support people with specialty diet and their families in aspects of educational, dining-out, home-cooking and school life, and to provide safe and convenience solutions on allergy-free diet.

Our services includes:

1. Professional Consultation & Allergy Test
2. Education
3. Dining-out Solutions
4. Consultation Service For Food Businesses
5. Freefrom Cooking Class
6. Low-allergen catering and lunch box services
7. Low-allergen fresh local bakery
8. Online Resources

For more information, please visit: https://www.freefromfoodsassociation.org/

For media enquiry, please contact:

Photo – https://photos.prnasia.com/prnh/20180528/2144387-1  

GENEVA, May 29, 2018 /PRNewswire/ —

• The theme of WHO World No Tobacco Day 2018 on 31 May is: “Tobacco breaks hearts, choose health and not tobacco”
• Smoking is associated with around 7 million global deaths per year and is an independent, major risk factor for myocardial infarction, stroke, heart failure and low quality of life
• The World Heart Federation is working with the WHO on the occasion of World No Tobacco Day to raise awareness of the link between tobacco and CVD, and to promote the immediate and long-term benefits of stopping smoking

World No Tobacco Day is a World Health Organization initiative that will be held on 31 May and this year will focus on raising awareness of the link between tobacco and cardiovascular disease (CVD). Tobacco is associated with around 7 million deaths worldwide every year, directly related to the consumption of and indirect exposure to smoke.

Smoking damages blood vessels and thickens blood. It increases blood rate and blood pressure and replaces oxygen, making it an important risk factor in the development of coronary disease, stroke and peripheral vascular disease. Furthermore, it is the second most prevalent cause of CVD after hypertension. Given that CVDs constitute the number one cause of death in the world, the World Heart Federation (WHF) applauds this initiative by the World Health Organization (WHO).

Despite the general public being familiar with the impact that tobacco causes on health, the WHO highlights the fact that it is rarely thought of as being one of the main causes for CVD. According to WHF President Professor David Wood: “Tobacco consumption constitutes the main avoidable risk for cardiovascular health. Because of this, it is our duty to help our patients with heart disease to quit smoking, and for those patients at high risk of having a heart attack or stroke to help them quit as well. By doing so we can help all our patients to reduce their risk but even more importantly we need to raise awareness and educate the general public about the impact tobacco on our hearts and crucially the importance of children and young people never starting.“

Almost 80% of the one billion smokers around the world live in average and lower income countries where the burden of illness and death associated with tobacco is much greater. With this in mind, WHF through its “Because every heartbeat matters” policy is promoting an agenda of greater access to care and the prevention, control and management of cardiovascular illnesses for everyone, regardless of status or circumstance, with the objective of extending and improving quality of life.

“We firmly believe in the need to continually highlight the risks of tobacco to the health of our hearts and circulation. By bringing together healthcare professionals, governments, institutions, industry and the general public around a common cause we can continue to educate people about the dangers of tobacco and unhealthy lifestyles, and promote the need for universal access to care,“ adds Prof. Wood. To aid this education, WHF will soon be releasing two fact sheets on smoking cessation: one for the general public and one for professionals.

On 29 September, WHF will be celebrating World Heart Day with the objective of raising awareness about the importance of good cardiovascular health. One of their key messages is around the immediate and long-term health benefits brought about by quitting smoking:

• Within just 20 minutes, heart rate and blood pressure drops
• 12 hours after stopping smoking, the carbon monoxide levels in blood drops and returns to normal levels
• Between 2 and 12 weeks, circulation will have improved and pulmonary function increased
• Over the first 9 months, coughing and breathlessness diminishes
• One year after quitting smoking, the risk of contracting a coronary disease is approximately half that of a smoker
• Between 5 and 15 years after quitting smoking, the risk of suffering from a cerebrovascular accident drops to that of a non-smoker
• 15 years after having quit smoking, the risk of suffering from a coronary disease equates to that of a non-smoker